DWTI announced final results for Fiscal 2009.

DWTI announced "Notice regarding completion of compound optimization for new anti-glaucoma drug".

DWTI issued new shares through Third Party Allocation.

DWTI announced Financial results for the third quarter of Fiscal 2009.

DWTI listed it's share to JASDAQ Stock Exchange NEO.

DWTI issued new shares through Third Party Allocation.

Dr. Hiroyoshi Hidaka, General Manager, Research & Development Laboratory, delivered a lecture at monthly meeting of Japan Pharmaceutical Licensing Association on “The future of small molecule drugs”.

DWTI announces new members for board of directors

Japan Patent Office to confirm Rho-kinase inhibitor patent.

DWTI announces a change in president position.